Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shield Therapeutics ( (GB:STX) ).
Shield Therapeutics has highlighted the growing clinical profile of its flagship ferric maltol product after an independent, peer-reviewed report on ACCRUFeR/FeRACCRU was published in the journal Pediatric Drugs. The paper reviews the recent U.S. FDA extension of ferric maltol’s indication to pediatric patients aged 10 and over, supported by data from the Phase 3 FORTIS study showing efficacy, safety and tolerability of a new liquid formulation in children as young as one month.
The publication reinforces ferric maltol’s positioning as a differentiated, well-characterised oral iron therapy and underscores its potential role in addressing underdiagnosed pediatric iron deficiency. By validating the pediatric data in a respected journal, the report is likely to support clinician awareness and uptake, strengthening Shield’s competitive standing as ACCRUFeR/FeRACCRU continues to build share as the leading branded prescription oral iron in the U.S. market.
The most recent analyst rating on (GB:STX) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on STX Stock
According to Spark, TipRanks’ AI Analyst, STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.
To see Spark’s full report on STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical group focused on treatments for iron deficiency and iron deficiency anemia. Its lead product, the oral iron therapy ACCRUFeR/FeRACCRU (ferric maltol), is marketed in the U.S., Europe, Canada and other territories through partners, targeting a large unmet need in a $2.3 billion iron deficiency market.
Average Trading Volume: 1,964,732
Technical Sentiment Signal: Hold
Current Market Cap: £84.41M
For an in-depth examination of STX stock, go to TipRanks’ Overview page.